Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.
Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ; AV45-A11 Study Group; AV45-A11 Study Group. Doraiswamy PM, et al. Among authors: joshi ad. Mol Psychiatry. 2014 Sep;19(9):1044-51. doi: 10.1038/mp.2014.9. Epub 2014 Mar 11. Mol Psychiatry. 2014. PMID: 24614494 Free PMC article.
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).
Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasić JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ. Wong DF, et al. Among authors: joshi ad. J Nucl Med. 2010 Jun;51(6):913-20. doi: 10.2967/jnumed.109.069088. J Nucl Med. 2010. PMID: 20501908 Free PMC article. Clinical Trial.
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Adler LP, Kovnat KD, Seibyl JP, Arora A, Saha K, Burns JD, Lowrey MJ, Mintun MA, Skovronsky DM; Florbetapir F 18 Study Investigators. Joshi AD, et al. J Nucl Med. 2012 Mar;53(3):378-84. doi: 10.2967/jnumed.111.090340. Epub 2012 Feb 13. J Nucl Med. 2012. PMID: 22331215 Free article.
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, Mintun MA, Skovronsky DM; AV-45-A16 Study Group. Clark CM, et al. Among authors: joshi ad. Lancet Neurol. 2012 Aug;11(8):669-78. doi: 10.1016/S1474-4422(12)70142-4. Epub 2012 Jun 28. Lancet Neurol. 2012. PMID: 22749065
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
Dugger BN, Clark CM, Serrano G, Mariner M, Bedell BJ, Coleman RE, Doraiswamy PM, Lu M, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Zehntner SP, Carpenter AP, Joshi AD, Mintun MA, Pontecorvo MJ, Skovronsky DM, Sue LI, Beach TG. Dugger BN, et al. Among authors: joshi ad. J Neuropathol Exp Neurol. 2014 Jan;73(1):72-80. doi: 10.1097/NEN.0000000000000028. J Neuropathol Exp Neurol. 2014. PMID: 24335535 Free PMC article.
279 results